GRAIL, Inc. (GRAL) Stock

GRAIL, Inc., headquartered in Menlo Park, California, is a pioneering biotechnology firm dedicated to advancing technologies for early cancer detection. Founded in 2015 and formerly known as PSC15, Inc., the company rebranded as GRAIL, Inc. in January 2016. GRAIL focuses on developing innovative screening and diagnostic solutions to detect cancer at its earliest stages, aiming to improve patient outcomes through early intervention.

Central to GRAIL's portfolio is Galleri, a groundbreaking screening test designed for asymptomatic individuals aged 50 and above. This test aims to detect multiple types of cancer early when they may be more treatable. Additionally, GRAIL develops the Diagnostic Aid for Cancer (DAC), which assists in accelerating diagnostic resolutions for patients with suspected cancer. Beyond screening and diagnostic aids, GRAIL is also advancing technologies for minimal residual disease and other post-diagnostic tests.

As a subsidiary of Illumina, Inc., GRAIL benefits from strategic collaborations and access to cutting-edge genetic sequencing technologies. Positioned within the biotechnology hub of Menlo Park, GRAIL continues to drive innovation in cancer detection, leveraging its scientific expertise and partnerships to push the boundaries of early cancer detection and improve global health outcomes.